Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
This is a 12-week study for the treatment of chronic persistent symptoms in participants with
schizophrenia. Participants on a stable, optimal dose of up to two atypical antipsychotics
who fulfill the screening criteria will be randomized to receive either an FDA-approved drug
or placebo in addition to the current treatment. Safety will be closely monitored through
vital signs, various tests, and blood and urine samples.